Been looking at pharmaceutical ETFs lately and honestly there's more variety out there than I realized. If you're trying to get exposure to the pharma sector without picking individual stocks, these funds can be a solid middle ground - you get the diversification of a basket but still trade like a regular stock.

The heavy hitters in pharmaceutical ETFs seem to be VanEck's PPH and iShares' IHE based on assets. PPH has been around since 2011 and holds about 26 companies with Eli Lilly and Novartis as top picks. IHE's slightly older, launched back in 2006, and it's loaded with major names - Johnson & Johnson and Eli Lilly make up nearly half the fund's weight there. Both have pretty reasonable expense ratios around 0.36-0.38 percent.

Then you've got Invesco's PJP and State Street's XPH if you want alternatives. PJP tracks 31 US pharma companies with a 0.57 percent fee, while XPH is interesting because it weights holdings more evenly across 52 companies instead of concentrating on just the mega-caps. That could appeal to people wanting more balanced sector exposure.

If you're looking internationally, the KraneShares KURE ETF focuses on Chinese healthcare stocks - different play entirely but worth knowing about if you want geographic diversification in pharmaceutical ETFs.

The main appeal of going with pharmaceutical ETFs instead of individual pharma stocks is obvious - even if one holding tanks, the rest of the fund buffers the damage. Plus the expense ratios are low enough that they don't eat into returns too badly. Data's from early 2026 so fairly current. Not financial advice obviously, just sharing what I've been researching.